Corbus Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, develops and commercializes novel therapeutics to treat inflammatory-fibrotic diseases. The company primarily develops Resunab, an oral anti-inflammatory drug that has completed Phase I clinical trials for the treatment of cystic fibrosis and diffuse scleroderma. It sells its products through hearing professionals, including audiologists, hearing aid specialists, and ENT doctors worldwide. The company was incorporated in 2009 and is based in Norwood, Massachusetts.